Prime Medicine, Inc. (PRME)
NASDAQ:PRME
PRME Stock Chart & Stats
$3.43
-$0.14(-4.27%)
At close: 4:00 PM EST
$3.43
-$0.14(-4.27%)
Day’s Range― - ―
52-Week Range$1.11 - $6.94
Previous CloseN/A
Volume144.88K
Average Volume (3M)2.39M
Market Cap
$619.29M
Enterprise Value$672.69M
Total Cash (Recent Filing)$177.68M
Total Debt (Recent Filing)$116.43M
Price to Earnings (P/E)―
Beta2.94
Next Earnings
May 07, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding180,552,190
10 Day Avg. Volume1,822,506
30 Day Avg. Volume2,394,600
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)4.27
Price to Sales (P/S)111.44
P/FCF Ratio-3.09
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue145.23
Enterprise Value/Gross Profit-250.16
Enterprise Value/Ebitda-3.44
Forecast
1Y Price Target
$5.50Price Target Upside60.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.93
Revenue Forecast (FY)$20.60M
Bulls Say, Bears Say
Bulls Say
Clinical Proof-of-conceptEarly clinical proof-of-concept and a favorable tolerability profile for PM359 support the potential of in vivo prime editing to correct the targeted Wilson disease mutation in liver cells, lowering development risk for the platform.
Commercial OpportunityProgress in the AATD program that addresses tolerability and dosing simplicity could capture a meaningful share of the affected patient population, creating a significant commercial opportunity if uptake occurs.
Regulatory StrategyEngagement with the FDA and pursuit of a biologics license application for PM359 could enable an accelerated approval pathway if clinical data satisfy regulatory expectations, reducing the time to potential market access.
Bears Say
Competitive LandscapeAn increasingly crowded AATD therapeutic landscape could intensify competition and constrain market share and pricing for the company's candidate even with positive clinical data.
Funding RiskHigh cash burn and a limited cash runway increase the likelihood that additional financing will be required, which could dilute existing holders or delay development plans.
Regulatory And Sector UncertaintyOngoing legal uncertainty and episodic volatility in the gene editing sector raise the risk of pronounced stock price swings and may keep investor confidence constrained despite scientific progress.
Prime Medicine, Inc. News
PRME FAQ
What was Prime Medicine, Inc.’s price range in the past 12 months?
Prime Medicine, Inc. lowest stock price was $1.11 and its highest was $6.94 in the past 12 months.
What is Prime Medicine, Inc.’s market cap?
Prime Medicine, Inc.’s market cap is $619.29M.
When is Prime Medicine, Inc.’s upcoming earnings report date?
Prime Medicine, Inc.’s upcoming earnings report date is May 07, 2026 which is in 24 days.
How were Prime Medicine, Inc.’s earnings last quarter?
Prime Medicine, Inc. released its earnings results on Mar 03, 2026. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.251 by $0.031.
Is Prime Medicine, Inc. overvalued?
According to Wall Street analysts Prime Medicine, Inc.’s price is currently Undervalued.
Does Prime Medicine, Inc. pay dividends?
Prime Medicine, Inc. pays a Quarterly dividend of $0.8 which represents an annual dividend yield of N/A. See more information on Prime Medicine, Inc. dividends here
What is Prime Medicine, Inc.’s EPS estimate?
Prime Medicine, Inc.’s EPS estimate is -0.25.
How many shares outstanding does Prime Medicine, Inc. have?
Prime Medicine, Inc. has 180,552,190 shares outstanding.
What happened to Prime Medicine, Inc.’s price movement after its last earnings report?
Prime Medicine, Inc. reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.251. Following the earnings report the stock price went down -9.227%.
Which hedge fund is a major shareholder of Prime Medicine, Inc.?
Currently, no hedge funds are holding shares in PRME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prime Medicine, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.50 (60.35% Upside)
$5.50 (60.35% Upside)
Blogger Sentiment
Bullish
PRME Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 6.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 1.0%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
193.16%
12-Months-Change
Fundamentals
Return on Equity
-178.61%
Trailing 12-Months
Asset Growth
25.81%
Trailing 12-Months
Company Description
Prime Medicine, Inc.
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
PRME Stock 12 Month Forecast
Average Price Target
$5.50
▲(60.35% Upside)
Technical Analysis
Immatics
―
Relay Therapeutics
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Upstream Bio, Inc.
―
Ownership Overview
Currently, No data available
---